Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer NCI Case Control Study

Document Type: Research Articles

Authors

1 Department of Surgical Oncology, National Cancer Institute, Cairo University, Egypt.

2 Department of Medical Oncology, National Cancer Institute, Cairo University, Egypt.

Abstract

Objectives: To assess the efficacy of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal
chemotherapy (HIPEC) in recurrent platinum-sensitive ovarian cancer patients in comparison with standard intravenous
chemotherapy in terms of progression free survival and overall survival. Methods: Retrospective case control study
matching 15 cases with 20 controls with at least 24 months of follow up. Results: The two groups were comparable
and well matched in all aspects. Median follow up was 36 months in cases and 38 months in controls. The PFS2
revealed a median of 6 months (range 2-14) in cases and 5 months (range 2-18) in controls. The median OS was 36
and 38 months in cases and controls respectively. No statistically significant difference between the cases and controls
were observed in progression free survival (PFS2) and overall survival OS (P-value, 0.350 and 0.711 respectively).
However, the PFS2 was in favor of cases and OS was in favor of controls without reaching significance. The percentage
of patients who survived 5 years or more was 20% in cases and 35% in controls. The only issue in favor of HIPEC
is the significant reduction in chemotherapeutic toxicity when given by the intraperitoneal way (P- value 0.003).
Conclusion: According to our study, CRS and HIPEC do not seem to have impact on OS and PFS in the setting of
recurrent platinum sensitive ovarian cancer. However, we recommend on going researches with much more refined
selection criteria and with larger sample size.

Keywords

Main Subjects